Dyadic International, Inc. (DYAI)

NASDAQ: DYAI · IEX Real-Time Price · USD
1.390
0.00 (0.00%)
Jul 19, 2024, 4:00 PM EDT - Market closed
0.00%
Market Cap 40.64M
Revenue (ttm) 2.26M
Net Income (ttm) -7.85M
Shares Out 29.24M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE 15.82
Dividend n/a
Ex-Dividend Date n/a
Volume 10,524
Open 1.410
Previous Close 1.390
Day's Range 1.360 - 1.460
52-Week Range 1.190 - 2.670
Beta 0.73
Analysts Strong Buy
Price Target 6.00 (+331.66%)
Earnings Date Aug 7, 2024

About DYAI

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein p... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 5, 2004
Employees 7
Stock Exchange NASDAQ
Ticker Symbol DYAI
Full Company Profile

Financial Performance

In 2023, DYAI's revenue was $2.90 million, a decrease of -1.07% compared to the previous year's $2.93 million. Losses were -$6.80 million, -30.20% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target
$6.0
(331.66% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with ...

23 days ago - GlobeNewsWire

Dyadic to Attend Industry Events in June

JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of prot...

7 weeks ago - GlobeNewsWire

Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor bi...

2 months ago - GlobeNewsWire

Dyadic to Attend Industry and Investor Events in May

JUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platform...

2 months ago - GlobeNewsWire

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scal...

2 months ago - GlobeNewsWire

Dyadic Reports 2023 Full Year Results and Recent Company Progress

JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scal...

4 months ago - GlobeNewsWire

Dyadic Announces Change in Board and Management Leadership Roles

JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scal...

4 months ago - GlobeNewsWire

Dyadic to Attend Industry Events in April

JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platfo...

4 months ago - GlobeNewsWire

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

JUPITER, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein...

4 months ago - GlobeNewsWire

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

JUPITER, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platfo...

4 months ago - GlobeNewsWire

Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024

JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building innovative ...

4 months ago - GlobeNewsWire

CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The ...

4 months ago - GlobeNewsWire

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein...

4 months ago - GlobeNewsWire

Dyadic to Attend Industry Events in March

JUPITER, Fla. , March 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platf...

5 months ago - GlobeNewsWire

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company f...

5 months ago - GlobeNewsWire

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced mi...

5 months ago - GlobeNewsWire

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced mi...

5 months ago - GlobeNewsWire

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

JUPITER, Fla. and LELAND, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq:...

5 months ago - GlobeNewsWire

Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a ful...

5 months ago - GlobeNewsWire

Dyadic to Attend BIO CEO & Investor Conference and European Industry Events

JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platfor...

6 months ago - GlobeNewsWire

Dyadic International, Inc Invites You to Join Us at The Microcap Conference

Jupiter, Florida--(Newsfile Corp. - January 22, 2024) - Dyadic International, Inc (NASDAQ: DYAI), Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial ...

6 months ago - Newsfile Corp

Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference

JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platfor...

7 months ago - GlobeNewsWire

Dyadic Attends Investor Events in December

JUPITER, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platfor...

8 months ago - GlobeNewsWire

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

Primary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant protein C1-cell produced antigen was both safe and well-tolerated No Serious Adverse Events reported Final Clinical ...

8 months ago - GlobeNewsWire

Dyadic's C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovativ...

8 months ago - GlobeNewsWire